Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of AFN0328 Injection for HPV16/18-associated cervical HSIL
CTR20262962Phase 2Active
- Sponsor
- Afana Biotechnology
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of AFN0328 in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by Afana Biotechnology. Started Jul 2026; status: active.
02
Drugs
AFN0328
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on CTR20262962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262962.